

Opportunity Title: FDA Trend Analysis and Data Mining of Bioequivalence Studies

Submitted in ANDAs

Opportunity Reference Code: FDA-CDER-2024-1436

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2024-1436

How to Apply *To submit your application, scroll to the bottom of this opportunity and click **APPLY**.*

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation. Your application will be considered incomplete, and will not be reviewed until one recommendation is submitted.

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE_FDA_CDER@orau.org. Please include the reference code for this opportunity in your email.

Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

Application Deadline 10/31/2024 3:00:00 PM Eastern Time Zone


Description ***Applications will be reviewed on a rolling-basis.**

FDA Office and Location: A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), located at Silver Spring, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This work covers more than just medicines.


Research Project: This project is in the Office of Study Integrity and Surveillance (OSIS), Office of Translational Science (OTS). The project is aimed to establish a statistical basis to ensure that the bioequivalence data submitted in Abbreviated New Drug Applications (ANDAs) are sound and comparable to the known clinical pharmacology of the drug. The project will compile historical pharmacokinetic data for select drugs and evaluate drug concentrations and pharmacokinetic parameters based on subject level data.


Learning Objectives: Under the guidance of the mentor, the participant will learn the principles, objectives, and conduct of bioequivalence studies submitted in support of ANDAs. The participant will also learn how CDER Offices evaluate bioequivalence studies to ensure that the data supporting generic drug approvals are reliable. The participant will learn and utilize statistical methodologies developed within the Agency to evaluate pharmacokinetic data across multiple ANDA applications. Through this project, the




ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 Google Play

Download on the
 App Store

Opportunity Title: FDA Trend Analysis and Data Mining of Bioequivalence Studies

Submitted in ANDAs

Opportunity Reference Code: FDA-CDER-2024-1436

participant will contribute to the overall understanding of drug concentration profiles originating from bioequivalence studies.

Anticipated Appointment Start Date: Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the [Guidelines for Non-U.S. Citizens Details page](#) of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice

Opportunity Title: FDA Trend Analysis and Data Mining of Bioequivalence Studies

Submitted in ANDAs

Opportunity Reference Code: FDA-CDER-2024-1436

during their fellowship;

- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should be currently pursuing or have received a master's or doctoral degree in the one of the relevant fields. Degree must have been received within the past five years, or anticipated to be received by 9/04/2024.

Preferred skills/ knowledge:

- Good understanding of bioequivalence studies
- Demonstrated analytical skills
- Strong Familiarity with Excel
- Data handling skills using R or Python
- Familiarity with R-Shiny

Eligibility Requirements • **Degree:** Master's Degree or Doctoral Degree received within the last 60 months or anticipated to be received by 9/4/2024 12:00:00 AM.

- **Discipline(s):**
 - **Chemistry and Materials Sciences** ([2](#))
 - **Computer, Information, and Data Sciences** ([3](#))
 - **Life Health and Medical Sciences** ([51](#))

Affirmation I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)

and

I have read the FDA Ethics Requirements.